AIMS: A recent study conducted in mice reported that liver-specific knockout of tumor suppressor Pten augments nuclear factor (erythroid-derived 2)-like 2 (NRF2) transcriptional activity. Here, we further investigated how phosphatase and tensin homolog deleted on chromosome 10 (PTEN) controls NRF2 and the relevance of this pathway in human carcin ogenesis. RESULTS: Drug and genetic targeting to PTEN and phosphoproteomics approaches indicated that PTEN leads to glycogen synthase kinase-3 (GSK-3)-mediated phosphorylation of NRF2 at residues Ser(335) and Ser(338) and subsequent beta-transducin repeat containing protein (β-TrCP)-dependent but Kelch-like ECH-associated protein 1 (KEAP1)-independent degradation. Rescue experiments in PTEN-deficient cells and xerographs in athymic mice indicated that loss of PTEN leads to increased NRF2 signature which provides a proliferating and tumorigenic advantage. Tissue microarrays from endometrioid carcinomas showed that 80% of PTEN-negative tumors expressed high levels of NRF2 or its target heme oxygenase-1 (HO-1). INNOVATION: These results uncover a new mechanism of oncogenic activation of NRF2 by loss of its negative regulation by PTEN/GSK-3/β-TrCP that may be relevant to a large number of tumors, including endometrioid carcinomas. CONCLUSION: Increased activity of NRF2 due to loss of PTEN is instrumental in human carcinogenesis and represents a novel therapeutic target.
AIMS: A recent study conducted in mice reported that liver-specific knockout of tumor suppressor Pten augments nuclear factor (erythroid-derived 2)-like 2 (NRF2) transcriptional activity. Here, we further investigated how phosphatase and tensin homolog deleted on chromosome 10 (PTEN) controls NRF2 and the relevance of this pathway in human carcin ogenesis. RESULTS: Drug and genetic targeting to PTEN and phosphoproteomics approaches indicated that PTEN leads to glycogen synthase kinase-3 (GSK-3)-mediated phosphorylation of NRF2 at residues Ser(335) and Ser(338) and subsequent beta-transducin repeat containing protein (β-TrCP)-dependent but Kelch-like ECH-associated protein 1 (KEAP1)-independent degradation. Rescue experiments in PTEN-deficient cells and xerographs in athymic mice indicated that loss of PTEN leads to increased NRF2 signature which provides a proliferating and tumorigenic advantage. Tissue microarrays from endometrioid carcinomas showed that 80% of PTEN-negative tumors expressed high levels of NRF2 or its target heme oxygenase-1 (HO-1). INNOVATION: These results uncover a new mechanism of oncogenic activation of NRF2 by loss of its negative regulation by PTEN/GSK-3/β-TrCP that may be relevant to a large number of tumors, including endometrioid carcinomas. CONCLUSION: Increased activity of NRF2 due to loss of PTEN is instrumental in humancarcinogenesis and represents a novel therapeutic target.
Authors: Daniel Martin; Ana I Rojo; Marta Salinas; Raquel Diaz; German Gallardo; Jawed Alam; Carlos M Ruiz De Galarreta; Antonio Cuadrado Journal: J Biol Chem Date: 2003-12-19 Impact factor: 5.157
Authors: Priyanka Tibarewal; Georgios Zilidis; Laura Spinelli; Nick Schurch; Helene Maccario; Alexander Gray; Nevin M Perera; Lindsay Davidson; Geoffrey J Barton; Nick R Leslie Journal: Sci Signal Date: 2012-02-28 Impact factor: 8.192
Authors: Gina M DeNicola; Florian A Karreth; Timothy J Humpton; Aarthi Gopinathan; Cong Wei; Kristopher Frese; Dipti Mangal; Kenneth H Yu; Charles J Yeo; Eric S Calhoun; Francesca Scrimieri; Jordan M Winter; Ralph H Hruban; Christine Iacobuzio-Donahue; Scott E Kern; Ian A Blair; David A Tuveson Journal: Nature Date: 2011-07-06 Impact factor: 49.962
Authors: Jeroen Frijhoff; Paul G Winyard; Neven Zarkovic; Sean S Davies; Roland Stocker; David Cheng; Annie R Knight; Emma Louise Taylor; Jeannette Oettrich; Tatjana Ruskovska; Ana Cipak Gasparovic; Antonio Cuadrado; Daniela Weber; Henrik Enghusen Poulsen; Tilman Grune; Harald H H W Schmidt; Pietro Ghezzi Journal: Antioxid Redox Signal Date: 2015-10-26 Impact factor: 8.401
Authors: Patricia Rada; Ana I Rojo; Anika Offergeld; Gui Jie Feng; Juan P Velasco-Martín; José Manuel González-Sancho; Ángela M Valverde; Trevor Dale; Javier Regadera; Antonio Cuadrado Journal: Antioxid Redox Signal Date: 2014-12-09 Impact factor: 8.401
Authors: Shaohua Ma; Chorlada Paiboonrungruan; Tiansheng Yan; Kevin P Williams; M Ben Major; Xiaoxin Luke Chen Journal: Ann N Y Acad Sci Date: 2018-05-11 Impact factor: 5.691
Authors: Dushani L Palliyaguru; Dionysios V Chartoumpekis; Nobunao Wakabayashi; John J Skoko; Yoko Yagishita; Shivendra V Singh; Thomas W Kensler Journal: Free Radic Biol Med Date: 2016-10-04 Impact factor: 7.376